Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 8/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 6/20 | 1.00 |
| ▸ | CETP | P11597 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3335404 | 0.91 | HDAC1 (0.84) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL28258088 | 0.88 | CETP (0.77) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL12323604 | 0.88 | CETP (0.77) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL28256535 | 0.88 | CETP (0.77) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL13703413 | 0.83 | HDAC3 (0.71) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL13783853 | 0.83 | HDAC3 (0.70) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL740382 | 0.82 | HDAC3 (0.68) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL19423434 | 0.81 | CETP (0.69) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL43074 | 0.81 | HDAC3 (0.69) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 | |
| SCHEMBL28734434 | 0.81 | CETP (0.69) | HDAC1HDAC2HDAC3CETPSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572368-B2 | Inhibitors of histone deacetylase | THE GENERAL HOSPITAL CORPORATION (US) | 2023-02-07 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662199-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2701699-B1 | INHIBITORS OF HISTONE DEACETYLASE | BROAD INST INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE, INC. (US) | 2018-04-12 | — | — | US | disclosed |
| US-9890172-B2 | Inhibitors of histone deacetylase | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2014-03-20 | — | — | US | disclosed |
| EP-2701699-A1 | INHIBITORS OF HISTONE DEACETYLASE | The Broad Institute, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149540-A1 | INHIBITORS OF HISTONE DEACETYLASE | THE BROAD INSTITUTE INC (US) | 2012-11-01 | — | — | WO | disclosed |
| CN-101001851-B | Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) | ASTELLAS PHARMA INC | 2011-04-20 | — | — | CN | disclosed |
| US-7557127-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2009-07-07 | — | — | US | disclosed |
| US-20090054464-A1 | HDAC INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7465731-B2 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| CN-101001851-A | Hydroxyamide compounds having activity as inhibitors of histone deacetylase (HDAC) | ASTELLAS PHARMA INC (JP) | 2007-07-18 | — | — | CN | disclosed |
| US-20060052599-A1 | HDAC inhibitor | ASTELLAS PHARMA INC. (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052599-A1 | HDAC inhibitor | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
| US-10662199-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20180099977-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-11572368-B2 | Inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20140080802-A1 | Inhibitors of Histone Deacetylase | HDAC2, HDAC1, HDAC11 | HDAC1 2/4885HDAC2 1/4885HDAC3 7/4885 |
| US-20090054464-A1 | HDAC INHIBITOR | HDAC1, HDAC2, HDAC8 | HDAC1 1/4885HDAC2 2/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.